Gallant

Completed Clinical Trials

As these trials move through the approval pipeline, they complete various phases before moving on to the next phase. Here’s the latest on the conditions for which we have completed specific phases, as well as information on our planned next steps.

FELINE CHRONIC KIDNEY DISEASE

Feline chronic kidney disease (CKD) is the number one killer of cats. There are currently no direct interventional therapies on the market to address this serious condition. Gallant’s cellular therapy is delivered intravenously (IV) has shown promise in a feline model of CKD. 

Gallant’s study of stem cell therapy for feline CKD has completed the pre-clinical phase. Stay tuned for more information as we prepare to begin the proof-of-concept phase

//images.ctfassets.net/9c9yhwtadln1/5JmnV3kezbkoUkzKlOQcCg/adb0b9a3a54aec466650a97c732873fd/CANINE_OSTEOARTHRITIS__OA_.png
CANINE OSTEOARTHRITIS

More than 20% of all dogs, especially older dogs, get canine osteoarthritis (OA), which can result in pain and inflammation of one or more joints.

Gallant’s stem cell therapy has demonstrated effectiveness and safety in a proof-of-concept pilot study of cells administered into the joints of dogs. 

We’ve also completed phase one of the study, which evaluated the effectiveness of GP-003 administered intravenously to dogs with OA. IV administration is the easier and preferred method of administration for cell therapies that do not require a specialist to perform difficult joint injections.

We plan to move on to phase two in mid-2024.

//images.ctfassets.net/9c9yhwtadln1/6KsJvWVZ9zkSHwdDDN5XGO/82249c0622b08e566e8658c80a2594fa/CANINE_ATOPIC_DERMATITIS__CAD_.png
CANINE ATOPIC DERMATITIS

Canine atopic dermatitis (CAD) is an allergic skin condition that affects more than 13 million dogs. Current therapies are either daily or monthly administration. Gallant’s cell therapy is designed to have a longer duration of action. Early pilot data in a placebo-controlled clinical trial suggest dogs may get a year or more of relief from a one-time therapy delivered IV.

Gallant has completed the phase one proof of concept and plans to start the phase two placebo-controlled large trial in 2025.

Interested in Becoming a Host Site for Future Trials?